Antibody engineering for the development of therapeutic antibodies

Cited 0 time in scopus
Metadata Downloads
Title
Antibody engineering for the development of therapeutic antibodies
Author(s)
Sang Jick Kim; Young Woo Park; Hyo Jeong Hong
Bibliographic Citation
Molecules and Cells, vol. 20, no. 1, pp. 17-29
Publication Year
2005
Abstract
Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 19 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, therapeutic antibodies are the second largest biopharmaceutical product category after vaccines. Antibodies have been engineered by a variety of methods to suit a particular therapeutic use. This review describes the structural and functional characteristics of antibody and the antibody engineering for the generation and optimization of therapeutic antibodies.
Keyword
affinity Maturationantibody engineeringantibody fragmentseffector functionshuman monoclonal antibodieshumanized antibodiespharmacokineticstherapeutic antibodies
ISSN
1016-8478
Publisher
South Korea
Type
Article
Appears in Collections:
Division of Biomaterials Research > Synthetic Biology and Bioengineering Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.